Neuromuscular blocking agents (NMBA) are among the most used medications in anesthesia. The appropriate use of NMBAs and their pharmacologic antagonists is dependent upon accurate assessment of the depth of neuromuscular blockade using objective indices obtained through quantitative neuromuscular monitors. Despite the widespread availability of these devices, their broad adoption remains sorely lacking.
Current data indicate an unacceptably high incidence of inappropriate management of neuromuscular blockade and a high rate of postoperative residual neuromuscular blockade and associated postoperative complications. In order to bridge the gap between evidence and practice, the American Society of Anesthesiologists (ASA) and the European Society of Anesthesiology and Intensive Care (ESAIC) recently published, independently from one another, Practice Guidelines for the Management of Neuromuscular Blockade recommending the use of quantitative neuromuscular monitoring in all patients receiving NMBAs.
In 2016, Erica M. Harris, CRNA co-lead the implementation of quantitative neuromuscular monitoring using electromyography at Duke University Medical Center. She will share her experience with implementation and discuss the principles and methods used over the past 7 years to encourage adoption of quantitative neuromuscular monitoring into clinical practice.
Who should attend
Anesthesiologists, certified registered nurse anesthetists,